Treatment of severe lichen planus with the JAK inhibitor tofacitinib - 08/06/20
Doi : 10.1016/j.jaci.2020.01.031
| This work was supported by the Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research (B.K.). W.D. is supported by the Dermatology Foundation. |
|
| Disclosure of potential conflict of interest: W. Damsky has research funding from Pfizer, but it did not support this work, and is a consultant for Eli Lilly. B. King is an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc; is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, Pfizer Inc, Regeneron, and Sanofi Genzyme; and is on speakers bureau for Pfizer Inc, Regeneron, and Sanofi Genzyme. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 145 - N° 6
P. 1708 - Giugno 2020 Ritorno al numero
Articolo precedente
- The potential of microRNAs as noninvasive biomarkers in acute pediatric asthma
- Aleksandra Trifunovic, Alan Dombkowski, Daniela Cukovic, Prashant Mahajan
- Primary prevention of asthma in high-risk children using HDM SLIT: Assessment at age 6 years
- Cherry Alviani, Graham Roberts, Frances Mitchell, Jane Martin, Zaraquiza Zolkipli, Louise J. Michaelis, Pandurangan Vijayanand, Ramesh Kurukulaaratchy, S. Hasan Arshad
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?